Log in or register
Share on LinkedInShare on LinkedIn

ARTICLE · 30 SEPTEMBER 2022

Insider Trading & Disclosure Update

Debevoise & Plimpton
Explore more from Debevoise & Plimpton

Welcome to the Fall 2022 issue of the Insider Trading & Disclosure Update, Debevoise's periodic Update focusing on legal, compliance and enforcement developments in the areas of insider...

United StatesCorporate/Commercial Law
Matthew E. Kaplan
Matthew E. Kaplan
Benjamin Pedersen
Benjamin Pedersen
Jonathan R. Tuttle
Jonathan R. Tuttle
Anna Moody
Anna Moody
Katherine Cappeller
Katherine Cappeller
Jonathan DeMars
Jonathan DeMars
Mark Flinn
Mark Flinn
Berk Guler
Berk Guler
Austin Poon
Austin Poon
+1 more

From the Editors

Welcome to the Fall 2022 issue of the Insider Trading & Disclosure Update, Debevoise's periodic Update focusing on legal, compliance and enforcement developments in the areas of insider trading, the management of material nonpublic information and disclosure rules and enforcement.

The nature and extent of the developments highlighted in this Update, including a number of pending SEC rule proposals and the first insider trading case in the digital asset space, illustrate a significant uptick in securities regulatory and enforcement activity at the SEC under Chair Gensler and on the enforcement front at the DOJ.

We hope that you find this Update useful and informative, and we look forward to bringing you further news and analyses in future issues.

We operate a free-to-view policy, asking only that you register in order to read all of our content. Please login or register to view the rest of this article.

Register for freeORLog in

The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.

Related Articles

Legal Intelligence Newsletters: sign up for the latest legal and regulatory news on your chosen topics

Read more about

Related Comparative Guides

See more popular content from

Article

Healthcare Trends & Transactions Q2 2026

Healthcare M&A activity maintained steady momentum through Q2 2026, driven by physician practice consolidation, AI-enabled technology acquisitions, and strategic outpatient expansion. Private equity investment persisted despite intensifying regulatory scrutiny of MSO arrangements, while digital health buyers paid significant premiums for platforms demonstrating production-grade AI capabilities and proprietary data assets.
United StatesCorporate/Commercial Law
Bass, Berry & Sims PLC
Bass, Berry & Sims PLC
Article

CLIENT ALERT: 2026 Mid-Year Update On SEC And CFTC Enforcement

The SEC and CFTC have fundamentally shifted their enforcement approach in 2026, moving away from high-volume technical violations toward targeted actions addressing serious fraud and market manipulation. This mid-year update examines new leadership priorities, enhanced inter-agency coordination, revised cooperation policies, the elimination of "no-deny" settlement provisions, and a landmark Supreme Court ruling on disgorgement that collectively reshape the regulatory landscape for market participants.
United StatesCorporate/Commercial Law
Sher Tremonte
Sher Tremonte
Article

Sanofi And Regeneron Expand Immunology Collaboration In Deal Worth Up To $8 Billion

Sanofi and Regeneron Pharmaceuticals announce a major expansion of their immunology partnership, committing up to $8 billion to develop and commercialize four long-acting antibodies targeting key inflammatory pathways. The collaboration includes a $1 billion upfront payment and milestone-based payments, with both companies sharing development costs and future profits equally.
United StatesCorporate/Commercial Law
Goodwin Procter LLP
Goodwin Procter LLP